These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 30762304)
41. Development and Validation of Physiologically Based Pharmacokinetic Model of Levetiracetam to Predict Exposure and Dose Optimization in Pediatrics. Shao W; Shen C; Wang W; Sun H; Wang X; Geng K; Wang X; Xie H J Pharm Sci; 2023 Oct; 112(10):2667-2675. PubMed ID: 37023853 [TBL] [Abstract][Full Text] [Related]
42. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Dallmann A; Ince I; Coboeken K; Eissing T; Hempel G Clin Pharmacokinet; 2018 Jun; 57(6):749-768. PubMed ID: 28924743 [TBL] [Abstract][Full Text] [Related]
43. Physiologically-based pharmacokinetic models for children: Starting to reach maturation? Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949 [TBL] [Abstract][Full Text] [Related]
44. Prediction of clearance and volume of distribution in the obese from normal weight subjects: an allometric approach. Mahmood I Clin Pharmacokinet; 2012 Aug; 51(8):527-42. PubMed ID: 22671778 [TBL] [Abstract][Full Text] [Related]
46. Misconceptions and issues regarding allometric scaling during the drug development process. Mahmood I Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):843-854. PubMed ID: 29999428 [TBL] [Abstract][Full Text] [Related]
47. Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population. Yee KL; Li M; Cabalu T; Sahasrabudhe V; Lin J; Zhao P; Jadhav P J Clin Pharmacol; 2018 Mar; 58(3):364-376. PubMed ID: 29077203 [TBL] [Abstract][Full Text] [Related]
48. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization. Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287 [TBL] [Abstract][Full Text] [Related]
49. Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans. Teitelbaum Z; Lave T; Freijer J; Cohen AF Clin Pharmacokinet; 2010 Sep; 49(9):619-32. PubMed ID: 20690784 [TBL] [Abstract][Full Text] [Related]
50. Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants. Tegenge MA; Mahmood I; Jiang Z; Forshee R J Clin Pharmacol; 2018 Jul; 58(7):877-884. PubMed ID: 29489016 [TBL] [Abstract][Full Text] [Related]
51. Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants. Duan P; Fisher JW; Yoshida K; Zhang L; Burckart GJ; Wang J Clin Pharmacokinet; 2017 Apr; 56(4):383-394. PubMed ID: 27596256 [TBL] [Abstract][Full Text] [Related]
52. Pediatric pharmacokinetic data: implications for environmental risk assessment for children. Ginsberg G; Hattis D; Miller R; Sonawane B Pediatrics; 2004 Apr; 113(4 Suppl):973-83. PubMed ID: 15060190 [TBL] [Abstract][Full Text] [Related]
53. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease. Tortorici MA; Cutler DL; Hazra A; Nolin TD; Rowland-Yeo K; Venkatakrishnan K J Clin Pharmacol; 2015 Mar; 55(3):241-50. PubMed ID: 25501531 [TBL] [Abstract][Full Text] [Related]
54. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072 [TBL] [Abstract][Full Text] [Related]
55. A model-based approach to dose selection in early pediatric development. Cella M; Gorter de Vries F; Burger D; Danhof M; Della Pasqua O Clin Pharmacol Ther; 2010 Mar; 87(3):294-302. PubMed ID: 20107435 [TBL] [Abstract][Full Text] [Related]
56. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583 [TBL] [Abstract][Full Text] [Related]
57. Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used? Salem F; Ogungbenro K; Vajjah P; Johnson TN; Aarons L; Rostami-Hodjegan A J Clin Pharmacol; 2014 Mar; 54(3):311-7. PubMed ID: 24122884 [TBL] [Abstract][Full Text] [Related]
58. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. Gerhart JG; CarreƱo FO; Edginton AN; Sinha J; Perrin EM; Kumar KR; Rikhi A; Hornik CP; Harris V; Ganguly S; Cohen-Wolkowiez M; Gonzalez D; Clin Pharmacokinet; 2022 Feb; 61(2):307-320. PubMed ID: 34617262 [TBL] [Abstract][Full Text] [Related]
59. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Mahmood I Clin Pharmacokinet; 2014 Apr; 53(4):327-46. PubMed ID: 24515100 [TBL] [Abstract][Full Text] [Related]
60. Dexmedetomidine pharmacokinetics in pediatric intensive care--a pooled analysis. Potts AL; Anderson BJ; Warman GR; Lerman J; Diaz SM; Vilo S Paediatr Anaesth; 2009 Nov; 19(11):1119-29. PubMed ID: 19708909 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]